According to a new report, published by KBV research, The Global Pigmentation Disorder Treatment Market size is expected to reach $1.2 billion by 2030, rising at a market growth of 4.8% CAGR during the forecast period.
The Melasma segment is showcasing a CAGR of 5% during (2023 - 2030). The treatment of melasma involves various approaches, including topical treatments, chemical peels, laser therapy, and combination therapies. This diversity in treatment options encourages individuals to seek professional advice and explore different treatments, driving market growth. The desire to improve skin appearance and reduce the visibility of melasma patches drives demand for treatments. Additionally, the increasing awareness of skin health and aesthetics will continue to drive demand for melasma treatments.
The Corticosteroids segment is leading the Global Pigmentation Disorder Treatment Market, By Treatment in 2022 thereby achieving a market value of $763.3 million by 2030. Corticosteroids have potent anti-inflammatory properties, making them useful for pigmentation disorders associated with inflammation or erythema (redness). Corticosteroids can help suppress these immune reactions. Corticosteroids provide relatively fast results, especially for reducing inflammation and erythema in disorders like post-inflammatory hyperpigmentation (PIH).
The Hospital Pharmacies segment has shown the high growth rate of 5.1% during (2023 - 2030). Hospital pharmacies typically stock specialized medications, including topical treatments, immunomodulators, and other pigmentation disorder-specific products. The role of hospital pharmacies in the pigmentation disorder treatment market can be significant in driving growth. Hospital pharmacies are crucial in distributing, dispensing, and administering medications and treatments for various medical conditions, including pigmentation disorders.
The North America region dominated the Global Pigmentation Disorder Treatment Market, By Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $439.9 million by 2030. The Europe market is anticipated to grow at a CAGR of 4.6% during (2023 - 2030). Additionally, The Asia Pacific market would witness a CAGR of 5.6% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/pigmentation-disorder-treatment-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bausch Health Companies Inc, Glenmark Pharmaceuticals Limited, Obagi Cosmeceuticals LLC, AbbVie, Inc., Dermavant Sciences, Inc. (Roivant Sciences Ltd.), Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Galderma S.A., Viatris, Inc. (Mylan N.V.), and Pfizer, Inc.
By Type
By Treatment
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
